NEW YORK (360Dx) – A multi-antibody platform that simultaneously analyzes information from about 30 biomarker proteins could be what primary care physicians need to detect pancreatic cancer early enough that something can be done to effectively treat it, according to the platform developer and pancreatic cancer researchers familiar with the test.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.